Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
Cellectis S.A.
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
Fred Hutchinson Cancer Center
Yale University
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center